Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC

This is a single-center, single-arm, exploratory clinical study evaluating the efficacy and safety of MRG003 (Becotatug Vedotin) in patients with relapsed small cell lung cancer. Eligible patients receive becotatug vedotin at a dose of 2.3 mg/kg administered by intravenous infusion once every 21 days until disease progression or unacceptable toxicity. The primary endpoint is overall survival (OS). Secondary endpoints include progression-free survival (PFS), objective response rate (ORR), and safety.

Trial Details

NCT ID
NCT07874581
Phase
NA
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • MRG003 (Becotatug Vedotin)
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Signed informed consent form (ICF);
  • Age ≥18 years at the time of signing informed consent;
  • Histologically confirmed small cell lung cancer (SCLC);
  • Extensive-stage SCLC (ES-SCLC) with disease progression or recurrence after prior treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →